Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.

Firas S AhmedLaurent DercleGregory V GoldmacherHao YangDana ConnorsYing TangSanja KarovicBinsheng ZhaoRichard D CarvajalCaroline RobertMichael L MaitlandGeoffrey R OxnardLawrence H Schwartz

Published in: European radiology (2020)

• Discordance between iRECIST and RECIST 1.1 was found in 12.8% of unresectable melanoma patients on pembrolizumab who continued therapy beyond initial RECIST 1.1-defined progression. • Pseudoprogression, captured with iRECIST, occurred in 17.9% and was significantly associated with improved overall survival in comparison with uncontrolled disease.

Keyphrases

phase ii
clinical trial
end stage renal disease
open label
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
double blind
peritoneal dialysis
phase iii
stem cells
patient reported outcomes
locally advanced
bone marrow
placebo controlled
rectal cancer
tyrosine kinase